DGAP-News: AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital
Retrieved on:
Monday, March 14, 2022
Biomarker, Partner, Drug development, Company, Research, Inflammation, MBH, Ayoxxa Biosystems, Efficiency, National University of Singapore, National university, Biology, Wellington Partners, CTO, Drug discovery, Stepstone, CSO, GHA, CEO, Proteomics, Vaccine, NRW.Bank, Drug, Security (finance), Management, Pharmaceutical industry, Fine chemical, EU, Prosnav Capital, AYOXXA, PROSNAV CAPITAL, AYOXXA
AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital
Key Points:
- AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital
The issuer is solely responsible for the content of this announcement. - The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network.
- "We are proud to have attracted Prosnav Capital as a shareholder.
- "With our LUNARIS(TM) platform, AYOXXA is well positioned to enter the commercial growth phase."